title: Chapter 6: Nasal polyps.
abstract: Nasal polyps occur in 1-4% of the population, usually occurring in the setting of an underlying local or systemic disease. The most common associated condition is chronic rhinosinusitis (CRS). A high prevalence of nasal polyps is also seen in allergic fungal rhinosinusitis, aspirin-exacerbated respiratory disease, Churg-Strauss syndrome, and cystic fibrosis. In the setting of CRS, nasal polyps are not likely to be cured by either medical or surgical therapy; however, control is generally attainable. The best medical evidence supports the use of intranasal corticosteroids for maintenance therapy and short courses of oral corticosteroids for exacerbations. The evidence for short- and long-term antibiotics is much less robust. For patients with symptomatic nasal polyposis nonresponsive to medical therapies, functional endoscopic sinus surgery provides an adjunctive therapeutic option.
authors.affiliation: Department of Medicine, Warren Alpert Medical School of Brown University Providence, Rhode Island, USA. russell_settipane@brown.edu
authors.forename: Russell A
authors.initials: RA
authors.lastname: Settipane
authors.forename: Anju T
authors.initials: AT
authors.lastname: Peters
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Chiu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D015897:Comorbidity; D004724:Endoscopy; D006801:Humans; D009298:Nasal Polyps / Q000453:epidemiology* / Q000628:therapy*; D010256:Paranasal Sinuses / Q000473:pathology / Q000601:surgery; D015995:Prevalence; D012220:Rhinitis / Q000453:epidemiology*; D012307:Risk Factors; D012852:Sinusitis / Q000453:epidemiology*
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents